Vaxxas PTY Ltd — Federal Contractor Profile
VAXXAS PTY LTD: $59.2M in Federal Contracts with No Recent Activity
Contractor Overview
Total Contract Value: $59,188,944 ($59.2M)
Total Awards: 2
Company Profile
VAXXAS PTY LTD is a federal contractor with a total government contract value of $59.2 million, spanning two contracts with an average size of $2,95,94,472. The company has not secured any recent contracts, indicating a potential slowdown or shift in their business strategy. VAXXAS PTY LTD does not have a sole-source or competitive contract pattern, suggesting a focus on specific, high-value contracts rather than a broad range of smaller, competitive bids. The lack of specific agency clients and recent contracts raises questions about the company's current engagement with federal agencies and its future prospects. Given the limited data, it is challenging to provide a detailed analysis of their capabilities, performance, and strategic direction. However, the company's significant contract size and the absence of competitive bidding suggest a specialized role in government contracting, possibly involving high-value, niche services or products.
Specializations
- Biomedical research
- Vaccines and immunization technologies
- Medical device development
- Clinical trials
- Regulatory compliance
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 0%
Agency Concentration: N/A
Growth Trajectory: N/A
Sole Source Rate: 0%
Recompete Rate: 0%
Competitive Position
Given the lack of recent contracts and the absence of competitive bidding, VAXXAS PTY LTD appears to be a niche player in the federal contracting market, possibly focusing on high-value, specialized services or products. The company's significant contract size and the absence of competitive bidding suggest a specialized role, but without more data, it is difficult to assess their market position relative to competitors.
Value to Taxpayers
The value to taxpayers is difficult to assess given the limited data. The company's high contract value and specialized nature suggest they may be providing high-value services, but without more information on the nature of the contracts and the cost-effectiveness of their services, it is challenging to determine if they are providing good value for the taxpayer's money.
Agency Relationships
The lack of specific agency clients and recent contracts raises questions about the company's current engagement with federal agencies. Without a clear dependency on any particular agency, it is difficult to assess the risk of concentration. However, the absence of recent activity may indicate a shift in the company's focus or a need for more information on their current client base.
Red Flags
- No recent contracts: This suggests a potential slowdown or shift in the company's business strategy.
- No competitive bidding: The absence of competitive bidding may indicate a focus on high-value, niche services or products, but it also raises questions about the company's market position and potential for cost escalation.
- Lack of agency concentration: The absence of specific agency clients makes it difficult to assess the risk of concentration and the company's dependency on any particular agency.
Green Flags
- High contract value: The significant contract size suggests the company is providing high-value services or products.
- Specialized services: The company's focus on specialized services or products may indicate a competitive advantage in niche markets.
- No sole-source awards: The absence of sole-source awards suggests the company is not relying on this type of contract, which may indicate a broader range of services or products.
Key Contracts
VAXXAS PTY LTD has secured two contracts with a total value of $59.2 million, each with an average size of $2,95,94,472. While the nature of these contracts is not specified, the significant contract size and the absence of competitive bidding suggest that the company is providing high-value, specialized services or products. The lack of recent contracts and the absence of specific agency clients make it difficult to assess the company's current engagement with federal agencies and its future prospects. The company's focus on high-value, niche services or products may indicate a competitive advantage in specialized markets, but without more information on the nature of the contracts and the cost-effectiveness of their services, it is challenging to determine if they are providing good value for the taxpayer's money.
Frequently Asked Questions
What does VAXXAS PTY LTD do for the federal government?
VAXXAS PTY LTD is a federal contractor that specializes in biomedical research, vaccines and immunization technologies, medical device development, clinical trials, and regulatory compliance. The company's focus on high-value, specialized services or products suggests they may be providing high-value services or products to the federal government, but the specific nature of their contracts is not specified.
How much taxpayer money does VAXXAS PTY LTD receive?
VAXXAS PTY LTD has secured a total of $59.2 million in federal contracts, with an average contract size of $2,95,94,472. The company has not secured any recent contracts, indicating a potential slowdown or shift in their business strategy.
Is VAXXAS PTY LTD good value for taxpayer money?
The value to taxpayers is difficult to assess given the limited data. The company's high contract value and specialized nature suggest they may be providing high-value services, but without more information on the nature of the contracts and the cost-effectiveness of their services, it is challenging to determine if they are providing good value for the taxpayer's money.
How does VAXXAS PTY LTD win its contracts?
Given the absence of competitive bidding, VAXXAS PTY LTD appears to be a niche player in the federal contracting market, possibly focusing on high-value, specialized services or products. The company's significant contract size and the absence of competitive bidding suggest a specialized role, but without more data, it is difficult to assess their market position and the specific strategies they use to win contracts.
What agencies use VAXXAS PTY LTD most?
The lack of specific agency clients and recent contracts raises questions about the company's current engagement with federal agencies. Without a clear dependency on any particular agency, it is difficult to assess the risk of concentration. However, the absence of recent activity may indicate a shift in the company's focus or a need for more information on their current client base.
What are the risks of relying on VAXXAS PTY LTD?
The risks of relying on VAXXAS PTY LTD include the potential for a slowdown or shift in their business strategy, the absence of competitive bidding, and the lack of specific agency clients. The company's focus on high-value, niche services or products may indicate a competitive advantage, but without more information on the nature of the contracts and the cost-effectiveness of their services, it is challenging to assess the full risk profile.
How does VAXXAS PTY LTD compare to similar contractors?
Given the limited data, it is difficult to provide a detailed competitive comparison. However, the company's focus on high-value, specialized services or products suggests they may be a niche player in the federal contracting market. The absence of competitive bidding and the lack of recent contracts may indicate a specialized role, but without more information on their competitors and the specific nature of their contracts, it is challenging to assess their market position relative to competitors in their specialty areas.
Recent Federal Contracts
Vaxxas PTY Ltd has 1 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| HHS awards $29.6M contract for pandemic influenza vaccine patch development | Department of Health and Human Services | $29.6M | N/A |